Status:
UNKNOWN
Efficacy of Apixaban in Malignancy With Deep Venous Thrombosis
Lead Sponsor:
Beni-Suef University
Conditions:
Deep Vein Thrombosis
Malignancy
Eligibility:
All Genders
20-80 years
Phase:
PHASE3
Brief Summary
The aim of study was to evaluate the efficacy and safety of Apixaban in patients with acute deep venous thrombosis and active malignancy compared with weight adjusted subcutaneous (LMWH). It was hypot...
Detailed Description
Patients with active malignancy have hypercoagulable state particularly, those receiving intravenous chemotherapy, with six fold higher risk of venous thromboembolism (VTE) \[1\]. Anticoagulation for ...
Eligibility Criteria
Inclusion
- Inclusion Criteria Patients with active malignancy presenting with acute deep venous thrombosis and still treated with chemotherapy
- Exclusion Criteria:
- Patients with pulmonary embolism and hemodynamic instability requiring thrombolytic therapy
- Previous DVT or venous thromboembolism
- Administration of LMWH or unfractionated heparin before randomization
- Brain tumours, cerebral metastes, hepatic tumours or impairment Child-Pugh B or C, -Recent or current active or life threating bleeding (e.g. intr acranial haemorrhage or gastrointestinal bleeding)
- Thrombocytopenia (platelets \<100 x 109L)
- Severe chronic kidney disease (estimated glomerular filtration rate \<30 ml/minute)
- Pregnant women
Exclusion
Key Trial Info
Start Date :
July 3 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 3 2020
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04462003
Start Date
July 3 2019
End Date
July 3 2020
Last Update
July 8 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine,Beni-Suef University
Banī Suwayf, Beni Suweif Governorate, Egypt, 62511